Rachel G Miller1, Tina Costacou2. 1. Department of Epidemiology, School of Public Health, University of Pittsburgh, 130 N. Bellefield Avenue, Pittsburgh, PA, 15213, USA. 2. Department of Epidemiology, School of Public Health, University of Pittsburgh, 130 N. Bellefield Avenue, Pittsburgh, PA, 15213, USA. CostacouT@edc.pitt.edu.
Abstract
PURPOSE OF REVIEW: Despite improvements in treatment, people with type 1 diabetes continue to have increased cardiovascular disease (CVD) risk. Glycemic control does not fully explain this excess CVD risk, so a greater understanding of other risk factors is needed. RECENT FINDINGS: The authors review the relationship between glycemia and CVD risk in adults with type 1 diabetes and summarize evidence regarding other factors that may explain risk beyond glycemia. Insulin resistance, weight gain, sex differences, genetics, inflammation, emerging markers of risk, including lipid subclasses and epigenetic modifications, and future directions are discussed. As glycemic control improves, an increased focus on other CVD risk factors is warranted in type 1 diabetes. Novel markers and precision medicine approaches may improve CVD prediction, but a lack of type 1 diabetes-specific guidelines for lipids, blood pressure, and physical activity are likely impediments to optimal CVD prevention in this high-risk population.
PURPOSE OF REVIEW: Despite improvements in treatment, people with type 1 diabetes continue to have increased cardiovascular disease (CVD) risk. Glycemic control does not fully explain this excess CVD risk, so a greater understanding of other risk factors is needed. RECENT FINDINGS: The authors review the relationship between glycemia and CVD risk in adults with type 1 diabetes and summarize evidence regarding other factors that may explain risk beyond glycemia. Insulin resistance, weight gain, sex differences, genetics, inflammation, emerging markers of risk, including lipid subclasses and epigenetic modifications, and future directions are discussed. As glycemic control improves, an increased focus on other CVD risk factors is warranted in type 1 diabetes. Novel markers and precision medicine approaches may improve CVD prediction, but a lack of type 1 diabetes-specific guidelines for lipids, blood pressure, and physical activity are likely impediments to optimal CVD prevention in this high-risk population.
Authors: Araz Rawshani; Naveed Sattar; Stefan Franzén; Aidin Rawshani; Andrew T Hattersley; Ann-Marie Svensson; Björn Eliasson; Soffia Gudbjörnsdottir Journal: Lancet Date: 2018-08-09 Impact factor: 79.321
Authors: Nicole C Foster; Roy W Beck; Kellee M Miller; Mark A Clements; Michael R Rickels; Linda A DiMeglio; David M Maahs; William V Tamborlane; Richard Bergenstal; Elizabeth Smith; Beth A Olson; Satish K Garg Journal: Diabetes Technol Ther Date: 2019-01-18 Impact factor: 6.118
Authors: Rachel G Miller; Hemant D Mahajan; Tina Costacou; Akira Sekikawa; Stewart J Anderson; Trevor J Orchard Journal: Diabetes Care Date: 2016-09-21 Impact factor: 19.112
Authors: V Gagnum; L C Stene; T G Jenssen; L M Berteussen; L Sandvik; G Joner; P R Njølstad; T Skrivarhaug Journal: Diabet Med Date: 2016-04-07 Impact factor: 4.359
Authors: David M Nathan; Bernard Zinman; Patricia A Cleary; Jye-Yu C Backlund; Saul Genuth; Rachel Miller; Trevor J Orchard Journal: Arch Intern Med Date: 2009-07-27
Authors: Steve Edelman; Fang Liz Zhou; Ronald Preblick; Sumit Verma; Sachin Paranjape; Michael J Davies; Vijay N Joish Journal: Pharmacoecon Open Date: 2020-09